2m 2m 2m 2m 2m 2m 2m
Biomarin Pharm (BMRN)
NASDAQ
$56.73+$0.83 (+1.49%)
Price as of Jun 23, 2026 1:50 PM EDT- $10.8BMarket Cap
- 3.37%1-Year Change
- BiotechnologyIndustry
Biomarin Pharm (BMRN)
$56.73+$0.83 (+1.49%)
Annual
Quarterly
12/31/2025 | 12/31/2024 | 12/31/2023 | 12/31/2022 | ||
|---|---|---|---|---|---|
Income Statement | |||||
Total Operating Revenue | 3.2B +11.00% | 2.9B +17.97% | 2.4B +15.42% | 2.1B +13.53% | |
Cost of Revenue | 717.4M +23.65% | 580.2M +12.70% | 514.9M +6.45% | 483.7M +2.80% | |
Gross Profit | 2.5B +7.77% | 2.3B +19.39% | 1.9B +18.11% | 1.6B +17.20% | |
Sales and Marketing Expense | 1.2B +14.27% | 1.0B +7.65% | 937.3M +9.75% | 854.0M +12.46% | |
Research and Development Expense | -921.9M +23.39% | -747.2M +0.06% | -746.8M +14.96% | -649.6M +3.31% | |
Depreciation and Amortization Expense | 79.6M -17.49% | 96.4M -7.63% | 104.4M +2.37% | 102.0M -5.62% | |
Total Operating Expenses | 2.8B +18.66% | 2.4B +4.80% | 2.3B +16.17% | 1.9B +0.93% | |
Operating Profit | 409.5M -15.43% | 484.2M +206.28% | 158.1M +5.71% | 149.6M +281.64% | |
Interest Income | 74.9M +0.03% | 74.9M +28.36% | 58.3M +223.49% | 18.0M +72.05% | |
Interest Expense | -9.5M -24.99% | -12.7M -26.56% | -17.3M +8.55% | -16.0M +4.13% | |
Interest Income and Expense and Net | 65.4M +5.15% | 62.2M +51.58% | 41.0M +1,886.63% | 2.1M +142.51% | |
Total Nonoperating Income and Expense | 9.5M -24.99% | 12.7M -26.56% | 17.3M +8.55% | 16.0M +4.13% | |
Income before Taxes | 482.5M -10.94% | 541.8M +187.31% | 188.6M +26.07% | 149.6M +298.51% | |
Income Taxes | 133.6M +16.25% | 114.9M +449.31% | 20.9M +160.99% | 8.0M +171.12% | |
Extraordinary Items | 125.0M +660.04% | 16.4M -57.40% | 38.6M N/A | N/A N/A | |
Net Income | 348.9M -18.26% | 426.9M +154.62% | 167.6M +18.43% | 141.6M +320.91% | |
Net Income from Continuing Operations Applicable to Common | 482.5M -10.94% | 541.8M +187.31% | 188.6M +26.07% | 149.6M +298.51% | |
Basic EPS and Net Income | 1.82 -19.11% | 2.25 +152.81% | 0.89 +17.11% | 0.76 +317.14% | |
Diluted EPS and Net Income | 1.80 -18.55% | 2.21 +154.02% | 0.87 +16.00% | 0.75 +314.29% | |
Basic Weighted Average Shares | 191.8M +0.93% | 190.0M +1.17% | 187.8M +1.39% | 185.3M +1.32% | |
Diluted Weighted Average Shares | 197.4M +0.35% | 196.7M +2.67% | 191.6M +1.39% | 189.0M +3.34% | |
Balance Sheet | |||||
Cash and Cash Equivalents | 1.3B +39.12% | 942.8M +24.86% | 755.1M +4.22% | 724.5M +23.37% | |
Short-Term Investments | 248.9M +27.75% | 194.9M -38.85% | 318.7M -43.80% | 567.0M +32.91% | |
Cash and Cash Equivalents and Short-Term Investments | 1.6B +37.17% | 1.1B +5.95% | 1.1B -16.86% | 1.3B +27.39% | |
Total Current Assets | 4.0B +22.31% | 3.2B +9.35% | 3.0B +7.44% | 2.8B +20.98% | |
Accumulated Depreciation | 1.1B +20.47% | 891.8M +2.85% | 867.1M +8.10% | 802.1M +11.32% | |
Property and Plant and Equipment and Net | 952.5M -8.68% | 1.0B -2.17% | 1.1B -0.67% | 1.1B +3.66% | |
Total Long-Term Assets | 277.0M +10.21% | 251.4M +46.55% | 171.5M -2.67% | 176.2M +16.13% | |
Total Assets | 7.6B +8.66% | 7.0B +2.15% | 6.8B +7.32% | 6.4B +6.19% | |
Income Taxes Payable | 3.7M -70.82% | 12.6M +374.05% | 2.7M -83.65% | 16.2M +415.03% | |
Total Short-Term Debt | 0 N/A | 0 -100.00% | 493.9M N/A | 0 N/A | |
Total Current Liabilities | 759.0M +25.05% | 607.0M -48.43% | 1.2B +99.87% | 588.9M +9.09% | |
Total Long-Term Debt | 597.2M +0.34% | 595.1M +0.34% | 593.1M -45.24% | 1.1B +0.37% | |
Total Long-Term Liabilities | 150.8M +17.07% | 128.8M +7.41% | 119.9M +19.92% | 100.0M +1.52% | |
Total Liabilities | 1.5B +13.23% | 1.3B -29.58% | 1.9B +6.67% | 1.8B +2.27% | |
Retained Earnings | 154.2M +179.20% | -194.7M -68.68% | -621.6M -21.24% | -789.2M -14.74% | |
Total Stockholders Equity | 6.1B +7.58% | 5.7B +14.27% | 5.0B +7.57% | 4.6B +7.78% | |
Total Shares Outstanding | 192.3M +0.81% | 190.8M +1.15% | 188.6M +1.26% | 186.3M +1.27% | |
Cash Flow | |||||
Cash from Operating Activities | 828.0M +44.54% | 572.8M +259.69% | 159.3M -9.46% | 175.9M -42.24% | |
Capital Expenditures | 103.0M +20.62% | 85.4M -11.65% | 96.7M -20.06% | 121.0M +26.56% | |
Cash from Investing Activities | -414.2M -403.49% | 136.5M +222.70% | -111.2M +455.41% | -20.0M -94.53% | |
Dividends Paid | N/A N/A | N/A N/A | N/A N/A | N/A N/A | |
Cash from Financing Activities | -42.4M -91.95% | -526.4M +2,711.17% | -18.7M +0.41% | -18.6M +38,754.17% | |
Financials Ratio | |||||
Gross Margin | 77.35% -2.91% | 79.67% +1.21% | 78.72% +2.33% | 76.92% +3.23% | |
Operating Margin | 12.93% -23.81% | 16.97% +159.63% | 6.54% -8.42% | 7.14% +260.00% | |
Return on Assets | 4.79% -22.48% | 6.17% +143.32% | 2.54% +10.92% | 2.29% +311.50% | |
Return on Equity | 5.94% -26.16% | 8.05% +129.30% | 3.51% +9.99% | 3.19% +308.53% | |
Revenue Growth | 11.00% -38.80% | 17.97% +16.53% | 15.42% +13.98% | 13.53% +1,874.86% | |
Current Ratio | 5.21 -2.19% | 5.33 +112.04% | 2.51 -46.25% | 4.67 +10.90% | |
Cash Ratio | 1.73 +11.25% | 1.55 +142.10% | 0.64 -47.85% | 1.23 +13.09% | |
Debt-to-Equity Ratio | 0.10 -6.75% | 0.11 -52.07% | 0.22 -6.71% | 0.24 -6.89% | |
Debt-to-Assets Ratio | 0.08 -7.75% | 0.09 -46.38% | 0.16 -6.47% | 0.17 -5.45% | |
Earnings & Revenue History
Debt-to-Assets
Cash Flow